- Arix Bioscience said it had invested $15m in new portfolio company Imara, which develops treatments for sickle cell disease and other hemoglobinopathies.

Arix had taken a 10% stake and its investment director Mark Chin would join Imara's board.

'Sickle cell disease affects a large and growing population across the world and is devastating for both patients and families,' chief executive Joe Anderson said.

'Imara is led by an exceptional team developing a novel, compelling approach to treating this difficult disease.'

'We look forward to working with the leadership team and our co-investors to help accelerate the development of this exciting company.'

At 1:27pm: [LON:ARIX] Arix Bioscience Plc share price was 0p at 147.5p

Story provided by